Financials in USD. Standardized financial statements.
A compact view of how Sangamo Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $39.55M | $57.80M | $176.23M | $111.30M | $110.70M | $118.19M | $102.43M | $84.45M | $36.57M | $19.39M |
| Revenue Growth? | -31.6% | -67.2% | +58.3% | +0.5% | -6.3% | +15.4% | +21.3% | +131.0% | +88.6% | 0.0% |
| Cost of Revenue? | $7.60M | $0 | $0 | $12.11M | $0 | $180.65M | $145.92M | $114.87M | $65.73M | $65.62M |
| Gross Profit? | $31.95M | $57.80M | $176.23M | $99.19M | $110.70M | -$62.45M | -$43.49M | -$30.41M | -$29.16M | -$46.23M |
| Gross Margin? | +80.8% | +100.0% | +100.0% | +89.1% | +100.0% | -52.8% | -42.5% | -36.0% | -79.7% | -238.4% |
| Operating Expenses? | $139.95M | $161.77M | $450.24M | $300.47M | $294.04M | $67.10M | $61.69M | $161.60M | $92.93M | $91.95M |
| Operating Income? | -$108.00M | -$103.97M | -$274.00M | -$201.28M | -$183.34M | -$129.55M | -$105.18M | -$77.15M | -$56.36M | -$72.56M |
| EBITDA? | -$100.40M | -$89.09M | -$96.80M | -$189.17M | -$165.70M | -$123.87M | -$101.25M | -$74.79M | -$54.86M | -$70.67M |
| Income Before Tax | -$123.50M | -$98.11M | -$262.90M | -$191.85M | -$177.99M | -$120.78M | -$95.42M | -$68.89M | -$54.57M | -$71.67M |
| Income Tax Expense | -$568,000 | -$167,000 | -$5.07M | $429,000 | $306,000 | $345,000 | $0 | $0 | $0 | -$14,000 |
| Net Income? | -$122.93M | -$97.94M | -$257.83M | -$192.28M | -$178.29M | -$121.00M | -$95.19M | -$68.33M | -$54.57M | -$71.66M |
| EPS? | $-0.44 | $-0.49 | $-1.48 | $-1.25 | $-1.23 | $-0.90 | $-0.68 | $-0.70 | $-0.70 | $-1.02 |
| Diluted EPS? | $-0.44 | $-0.49 | $-1.48 | $-1.25 | $-1.23 | $-0.90 | $-0.68 | $-0.70 | $-0.70 | $-1.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality